Embed Size (px)
Citation preview
20 - 21 February 2020 | Lisbon, Portugal
LIQUID BIOPSY SUMMIT
Latest findings on the clinical
applications of CTCs, ctDNA, miRNAs
and exosomes in real t ime monitoring
of systemic anticancer therapies will
be discussed only at the Liquid
Biopsy 2020.
Experts will present and consider
process and technology refinements
that can enable molecular l iquid
biopsies to become a fulcrum in the
future of precision medicine.
Group
B I O T E CHPHARMASUMM I TOn 20 and 21 February 2020, Lisbon
(Portugal) will host the BioTech
Pharma Summit: Liquid Biopsy 2019
conference.
This year’s event will bring together
the leaders in the field from pharma,
biotech, Dx companies and healthcare
and be the home of multi-stakeholder
and pan-industry collaboration for
l iquid biopsy, molecular pathology
and precision medicine experts to
explore the expanding and evolving
field whereby Circulating Biomarkers
of various classes are being evaluated
for their potential to be developed into
diagnostics for cancer as well as
application of l iquid biopsy testing,
across biofluids, biomarkers and
disease indications, as the needle
shifts on the gold standard of
personalized healthcare testing.
WHO SHOU LD A T T E ND
CEOs, VPs, Drug developers, Academics and Researchers,
CROs, Scientists and Medical Doctors of :
• L iquid biopsy
• Cl inical Pathology
• Molecular Assay
Development
• Medical Laboratory
• Scientific Affairs
• Sales and Marketing
• Quality Management
• Process Development
• Commercial & Outreach,
Oncology
• Molecular pathology
• Research Scientist
• Molecular Biology
• Sales & Business
Development
• Cl inical and Translational
Affairs
• Cl inical Research
• Companion Diagnostics
• Biomarkers
• Manufacturing
• Scientific Affairs
• Cl inical Trial
• Oncology Business
Development
• Precision medicine
• Cl inical Laboratory
• Immunochemistry
• Cell Culture
• Cl inical Genomics
• Liquid Biopsy: New Opportunities, Technologies, and Challenges in the Field
• Clinical integration of l iquid biopsy
• Circulating Tumor Cells : History and Future Perspectives
• Improving the Quality of Circulating Tumor DNA Measurements
• Circulating Tumor Cells in Monitoring Cancer
• Extracellular vesicles (Evs)
• New Tools for Liquid Biopsies: Microfluidic Platforms for the Isolation of CTCs, cfDNA and Exosomes
• CTC Isolation Platforms and Using CTCs for Monitoring Therapy Responses
• Dissecting Mechanisms of Breast Cancer Metastasis Using Patient-Derived Circulating Tumor Cells
• Liquid Biopsies in Cancer Immunotherapy Clinical Drug Development
• Heterogeneity of Cancer-Derived Extracellular Vesicles
• Liquid Biopsies in Oncology and the Current Regulatory Landscape
• Validating Liquid Biopsies in Cancer
• ctDNA Liquid Biopsy Assay
K E Y P R AC T I C A LL E A RN I NG PO I N T S
GE
DR. DAGMAR KASPER
at Agena Bioscience
Managing Director (EMEA)
DK
DR. RASMUSBRØNDUM
at Leymus Genomics
CEO, Founder
DR. CECILIA SCHOTT
at Novartis
Head Precision Medicine Strategy
US
DR. DANIEL GRÖLZ
at QIAGEN
Scientific Associate Director R&D
DE
DR. CARLO BOTTARI
at NGS- HTGMolecular Diagnostics
Biomarker Signatures
UK
ES
DR. CLOTILDE COSTA NOGUEIRA
at Chus Joint Unit
Head of the Liquid Biopsy Line of the Roche
DR. GUOLIANG FU
Founder and CEO
at Genefirst ltd
UK
IT
DAVIDE ZOCCO
at Exosomics
Chief Technology Officer
DR. CATHERINE ALIX-PANABIÈRES
Director of LCCRH
at IURC
FR
DR. FRANÇOISE FARACE
FR
Head of RareCirculating Cell Translational Platform
at INSERM
DR. ANDERSSTÅHLBERG
Associate Professor
at the University of Gothenburg and Sahlgrenska University Hospital in Sweden
SE DE
PROF. DR. JENS K.HABERMANN
at Iqvia
President of ESBB
DR. ARJAN TIBBE
CEO
at VyCAP
NL
DR. CHRISTIAN WERNO
Group Leader, Preclinical Therapy Models
at Fraunhofer-Institut
DEUK
DR. LARASTEVANATO
at ANGLE plc
R&D Manager
PT
DR. LORENA DIÉGUEZ
at INL
Group LeaderMedical Devices
S P E AK E R S
SE
PROF. MIKAEL KUBISTA
at TATAA Biocenter
Chairman of the board and founder
SC I E N T I F I CAG ENDA
DAY 1
14:30 Metastasis is responsible for 90% of cancer related deathsBy Clotilde Costa Nogueira - Head of the Liquid Biopsy Line of the Roche at Chus Joint Unit
CTCs are responsible for distal metastasis are of great interest for biomarkers discovery to predict and monitor tumor progression and therapy failure. In this study we performed a monitoring of metastatic breast cancer patients before and after treatment througout CTC molecular characterization to identify biomarkers with interest for clinical oncology translation
14:30 Single cell isolationBy Arjan Tibbe - CEO at VyCAP
Single cell secretion
16:20 CTC Isolation Platforms and UsingBy Lorena Diéguez - Group Leader, Department of Life Sciences, Nano4Health Unit, Medical Devices Research Group, International Iberian Nanotechnology Laboratory
CTCs for Monitoring Therapy Responses
Circulating Tumor Cell isolation and analysis
15:50 Coffee & Networking Break
18:00 Chairman’s Closing Remarks
19:00 Gala Dinner
17:00 Circulating Tumor Cells: Finding Rare Events for a Huge Knowledge of Cancer DisseminationBy Catherine Alix - Panabières is the Director of this unique platform LCCRH- Université de Montpellier, Institut Universitaire de Recherche Clinique (IURC)
Technologies for detection of viable Circulating Tumor cells (CTCs)
Understanding the biology of CTCs
What about culturing CTCs in vitro to know more about metastasis-competent CTCs ?
17:40 Panel discussion: New Tools for Liquid BiopsiesWith speakers of both days
Advancements in microfluidic technologies
Microfluidic Platforms for the Isolation of CTCs, cfDNA and Exosomes
Progress in Circulating Tumor Cell Research Using Microfluidic Devices on clinical research parameters, such as survival statistics
Registration and Welcome Coffee08:00
08:50 Opening of the BioTech Pharma Summit
09:40 Speed Networking
10:20 Morning Coffee & Networking Break
12:50 Business Lunch
Thursday, February 20, 2020
09:00 Liquid Biopsy: Market TrendsBy Rasmus Brøndum - CEO, Founder at Leymus Genomics
Liquid biopsies 2019
Requirements for ctDNA analysis - What does extra analytes add to standard ctDNA assays e.g. proteins, RNA
Market outlook
Liquid biopsy analyses of human cancer is the future
11:30 Precision Medicine Using Liquid BiopsiesBy Lara Stevanato - R&D manager at ANGLE plc
ParsortixTM system microfluidic technology
Antigen independent capture of CTCs
Broad range of downstream analysis (Cytology, immunofluorescence, FISH, and molecular analysis)
Clinical applications to harvest cancer cells from patient blood and sample to answer (ParsortixTM system plus HyCEAD technology)
12:10 Clinical integration of liquid biopsyBy Christian Werno - Group Leader, Preclinical Therapy Models- Fraunhofer-Institut
CTCs are already used to predict disease progression and survival in metastatic patients, however functional analysis of ex vivo expanded CTCs remain challenging. We have generated CTC-derived in vivo and in vitro models from metastatic cancer patients. We have molecularly characterized these models and performed drug screens to improve personalized treatment strategies for metastatic patients in future
13:50 Circulating Tumor Cells in Monitoring CancerBy Françoise Farace - Head of Rare Circulating Cell Translational Platform CNRS UMS3655 at INSERM
The identification of predictive biomarkers of sensitivity and resistance to targeted therapies in non-small cell lung cancer, single CTC analyses and CTC-derived xenograft models for a better understanding of the mechanisms of therapeutic resistance and metastatic progression. I think my presentation could fit the session entitled
10:50 Clinical Practice is Shaping the Precision Medicine Ecosystem: focus on liquid biopsiesBy Cecilia Schott - Head Precision Medicine Strategy, Oncology Business Unit at Novartis
New diagnostic platforms are being developed, such as liquid biopsy, to identify the patient most likely to respond to a given treatment
There is an ever growing need to understand the precision medicine landscape thought the eyes of the practicing clinician
Geographical differences in the access to various testing modalities and reimbursement must be accounted for in clinical development programs and go-to-market strategies
An overview of the considerations for the global development and life cycle management of patient diagnostic and monitoring tools
DAY 2
14:10 Applications of CTCs and ctDNA as a Non-Invasive Tumor TrackerBy Dagmar Kasper - Managing Director (EMEA) at Agena Bioscience
14:50 Targeting tumor heterogeneity and applying liquid biopsiesBy Jens K Habermann - President of ESBB at Iqvia
13:10 Business Lunch
15:30 Coffee & Networking Break
17:00 Chairman’s Closing Remarks & End of Summit
12:30 Quantitative miRNA ProfilingBy Carlo Bottari - Biomarker Signatures, Molecular Diagnostics, CDx, Precision Medicine, Early Cancer Detection, Molecular Profiling, NGS at HTG Molecular Diagnostics
Methods and Challenges
16:00 Novel Technologies By Guoliang Fu - Founder and CEO- genefirst ltd
MMD-PCR (Multiplex Mutation Detection PCR)
17:40 Panel discussion: Conclusions and future directionsWith speakers of both days
Relevancy to utilize CTCs and ctDNA during systemic therapy rather than as early diagnosis markers
Tests for mutations in genes encoding therapeutic targets
A paradigm shift in liquid biopsy research with EVs or ctDNA being preferred markers over CTC
Technical challenges involved in removing Evs
Friday, February 21, 2020
Registration & Coffee08:00
08:30 Opening Address from the Chairperson
10:40 Morning Coffee and Networking Break
08:40 Circulating tumor DNA- preanalytical considerations, international specimen improvement requirements, standards, legislation, technologiesBy Daniel Grölz - Scientific Associate Director R&D, Sample Technologies Department at QIAGEN
Need of specimen quality improvement to reduce diagnostic errors
Pre-analytical factors that influence the outcome of ccfDNA analysis
International initiatives and requirements to standardize pre-analytical workflows
Liquid biopsy preservation and workflow solutions
10:00 Liquid Biopsies in Cancer Immunotherapy Clinical Drug DevelopmentBy TBA
Robustness, reproducibility and consistency across laboratories
The expected standards for analytical validation of a liquid biopsy assay
ctDNA and CTC strengths and weaknesses
11:10 Extracellular vesicles (EVs)By Davide Zocco - Chief Technology Officer- Exosomics
The performance of common exosome isolation methods
The integration of microfluidics and various sensing components or sensors
Microfluidic isolation of Evs
On-chip detection and analysis of Evs
11:50 Two-Tailed PCR for Precision DiagnosticBy Mikael Kubista - Chairman of the board and founder at TATAA Biocenter
Two-Tailed PCR
Ultra-sensitive microRNA profiling
Ultra-specific rare mutation analysis
Quality assessment of liquid biopsy testing
09:20 Technical and biological challenges when analyzing cell-free tumor DNABy Anders Ståhlberg - Associate Professor at the University of Gothenburg and Sahlgrenska University Hospital in Sweden
Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA
We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input. Here, we will present recent updates
Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine
We will show data from various ongoing studies, related to both clinical and basic research questions
B I OG RA PH I E S
Lara Stevanto possesses a PhD in Biotechnology. She joined ANGLE PLC in 2016 as R&D project manager for the analytical evaluation of ParsortixTM system as part of the FDA application. As part of Cancer-ID, she led the protocol development for the CTC isolation and enumeration technology comparison (CANCER-ID Ring Trial ). Prior to joining ANGLE, Lara served as Head of Molecular Biology at ReNeuron, specializing in the development of stem cell-based clinical products.
LARA STEVANATO , UKR&D Manager at ANGLE plc
Having gained a BSc in biochemistry, over the past 18 years, Carlo has been working in sales and marketingin the scientific technology industry. In his role at HTGhe is focused on Molecular Profiling, Biomarker Signature Development and Molecular Diagnostic Applications, including development of applications in Liquid Biopsy, Early Disease Detection, Companion Diagnostics and Precision Medicine.
CARLO BOTTARI, UKBiomarker Signaturesat NGS- HTGMolecular Diagnostics
Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the develop-ment of molecular assays for detection of EV shuttled mutations. In 2015 he took on the role of the Head of Molecular Diagnostics. Today he is responsible for development of EV-DNA and EV-RNA targeted solutions and for management of clinical testing of assay prototypes. Davide actively participates in scouting for new technologies, as well as internal IP strategy and pre-market launch of RUO and diagnostic kits.
DAVIDE ZOCCO, ITChief Technology Officerat Exosomics
Anders Ståhlberg is working as principal investigator at the Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital in Sweden. Anders primary research interest is to understand molecular mechanisms in tumor initiation and tumor development, focusing on breast cancer and sarcomas. He has developed several strategies for DNA and RNA, especially at the single-cell and single-molecule level.
ANDERS STÅHLBERG, SEAssociate Professor at the University of Gothenburgand Sahlgrenska University Hospital in Sweden
Professor Jens K. Habermann, m.d., Ph.D., is director of ICB-L (Interdisciplinary Center for Biobanking-Lübeck) and scientific director of UCCL (University Cancer Center Lübeck) at the University of Lübeck and University Clinic Schleswig-Holstein. As specialist in human genetics, he combines clinical routine, biobanking, and cancer research to optimize individualized medicine by targeting tumor heterogeneity and applying liquid biopsies.
JENS K. HABERMANN, DEPresident of ESBBat Iqvia
Clotilde is a Biologist. In 2011 I developed my phD in Molecular Oncology at CIEMAT (Madrid) focused on the study of cell cycle genes in squamous cell carcinomas. In 2013 she moved to Santiago de Compostela to the Translational Medical Oncology Group to work in the study of metastasis through Liquid Biopsy. Since 2015 she is the leader of the Liq-uid Biopsy Line at the Joint Unit Roche-Chus, University Clinical Hospital of Santiago, focused on the understanding of the biology of Circulating Tumor Cells of metastatic Breast and Prostate patients.
CLOTILDE COSTA NOGUEIRA, ESHead of the Liquid Biopsy Line of the Roche at Chus Joint Unit
Françoise Farace is currently in charge of the Translational Laboratory of Rare Circulating Cells at CNRS UMS3655 - INSERM US23 AMMICA, and of the Circulating Tumor Cells team at INSERM U981, Gustave Roussy. For the past fourteen years, FF focused her research on rare circulating cells such as circulating endothelial cells and circulating tumor cells with the goal of identifying both sensitivity and resistance biomarkers of anticancer therapies.
FRANÇOISE FARACE, FRHead of RareCirculating Cell Translational Platform at INSERM
In 1996 Kubista invented the light-up probes, which led to the foundation of LightUp Technologies AB as Europe´s first company focusing on qPCR based diagnostics. He co-founded MultiD Analyses AB, which develops the market leading software GenEx for molecular analysis, and in 2001 Kubista set up TATAA Biocenter as the first laboratory in Europe to obtain flexible ISO 17025 accreditation.
MIKAEL KUBISTA, SEChairman of the board and founder at TATAA Biocenter
ARJAN TIBBE , NL CEO at VyCAP
After completing his PhD in 2001, Arjan established and managed Im-municon Europe, Enschede, the Netherlands, a subsidiary of Immunicon Corporation, USA. Immunicon developed the FDA cleared CellSearch system for monitoring metastatic cancer by measuring the numberof CTC. Immunicon was ac-quired by Veridex, a Jonhson& Johnson company, in 2008 where he held the same position within the Enschede facility.
Dr. rer. med. Christian Werno is research group leader “Preclinical Therapy Models”, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Division of Personalized Tumor Therapy. He got his PhD at Goethe University Frankfurt am Main, then being a postdoctoral fellow at Fraunhofer ITEM Regensburg Division of Personalized Tumor Therapy.
CHRISTIAN WERNO, DEGroup Leader, PreclinicalTherapy Modelsat Fraunhofer-Institut
During this last decade, Dr Alix-Panabières has focused on optimizing new techniques of enrichment, detection and characterization of viable circulating tumor cells (CTCs) in patients with solid tumors. She is the expert for the EPISPOT technology that is used to detect viable CTCs in patients with breast, prostate, colon, head & neck cancer and melanoma. This technology has been recently improved to detect functional CTCs at the single cell level (EPIDROP).
CATHERINE ALIX-PANABIÈRES , FRDirector of LCCRH at IURC
RASMUS BRØNDUM, DKCEO, Founder at Leymus Genomics
Rasmus Brøndum, Molecular Biologist by training has worked for the leading companies in the genomic industry includ-ing companies such as Thermo Fisher Scientific, Illumina and Roche. At Roche as a director in Molecular Diagnostics he was part of a regional team launching worlds first liquid biopsy ( Cobas™ EGFR mutation test ). In 2016 he founded his own company Leymus Genomics which provides products for long read sequencing on Illumina sequencers and also big data on site storage for mainly clinical and national genome projects.
CECILIA SCHOTT, US Head Precision Medicine Strategyat Novartis
Cecilia is Head Precision Medicine Strategy Oncology Business Unit at Novartis. Prior to her current role Cecilia held positions VP, Precision Medicine for AstraZeneca Global Product & Portfolio Strategy, Global Marketing and US Medical Affairs. Cecilia background includes roles in the biotech and device industries. Before joining AstraZeneca she was part of Biogena Drug Safety and Medical Information function, and at Boston Scientific she was responsible for establishing the drug eluting stent franchise Medical Publications and Medical Information groups as part of Medical Affairs.
Dr. Grölz is the R&D project manager who led an international team within PreAnalytiX GmbH to develop the PAXgene Tissue and the PAXgene Blood ccfDNA Systems. He was the leader for the evaluation of the PAXgene Tissue System within the European collaborative grant project, SPIDIA, and manages work packages in two other grant projects to evaluate the PAXgene Tissue and PAXgene Blood ccfDNA Systems for use in routine pathology workflows. He is the main inventor of the PAXgene Tissue System and inventor/co-inventor of the PAXgene Blood ccfDNA stabilization chemistry.
DANIEL GRÖLZ, DEScientific Associate Director R&D at QIAGEN
Lorena Diéguez joined INL in 2014 as Staff Researcher and is, since May 2018, the leader of the Medical Devices research group. Her research is focused in the development of biomicrofluidic devices mainly devoted to Translational Medical Research in close collaboration with Hospitals. Her work is devoted to the development of integrated biosensing systems and nanobioengineered diagnostics microsystems for the isolation and characterization of Tumor Cells from body fluids of cancer patients, as well as the development of microfluidic organ-on-a-chip 3D models.
LORENA DIÉGUEZ, PTGroup Leader Medical Devices at INL
All Prices displayed include VAT @ The VAT amount will be displayed after the payment process and shown on your invoice.
Name:
Position:
E-mail:
Title:
Name:
Position:
E-mail:
Title:
Academic/ Med./ NPO Package
Industry Package
Premium Package
Super Early BirdUntil Nov 15
500€
1,495€
2,800€
Early BirdUntil Dec 13
600€
1,695€
3,000€
Discounted TicketUntil Jan 31
650€
1,795€
3,250€
Normal TicketAfter Jan 31
850€
1,995€
3,550€
*The Liquid Biopsy Summit is an exclusive limited seat event. Early bird tickets are non-refundable and subject to availability
PACKAGE NAME
Team Discounts
2 Delegates
3 Delegates
4+ Delegates
Until Nov 15
10%
15%
20%
Until Dec 13
5%
10%
15%
Until Jan 31
-
5%
10%
After Jan 31
-
-
5%
ACADEMIC/ MED./ NPO PACKAGE
2 days Summit
Full-Access to All Sessions
Coffee Breaks/Lunches
Gala Dinner (Extra 50€)
Unique 1-on-1 meetings
Airport Pick-Up/Drop-Off
Accommodation at the Hotel Venue
Individual or Group RegistrationINDUSTRY BASIC PACKAGE
2 days Summit
Full-Access to All Sessions
Coffee Breaks/Lunches
Gala Dinner
Unique 1-on-1 meetings
Airport Pick-Up/Drop-Off
Accommodation at the Hotel Venue
Individual RegistrationINDUSTRY PREMIUM PACKAGE
2 days Summit
Full-Access to All Sessions
Coffee Breaks/Lunches
Gala Dinner
Unique 1-on-1 meetings
Airport Pick-Up/Drop-Off
Accommodation at the Hotel Venue
Individual Registration
Address:
VAT No:
Company:
Signature:
City:
Date
Postcode:
Phone
Gala Dinner
This booking is invalid without signature
*Please send the signed form to this contact.
Diogo Lino RibeiroProject Director, Europe | Porto Office
PH: +351 915 239 640
R E G I S T R A T I O N
By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.
ConfirmationWe will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.CancellationsCancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.
Force MajeureWhile every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.CopyrightAll Intellectual Property rights in all materials produced or distributed by EPM Group in connection with this event are expressly reserved and any unauthorized duplication, publication or distribution is prohibited.
SILVER SPONSORSHIP
Opportunity to give a speech at the beginning of the conference[up to 40min]8m2 exhibition space with LCD Monitor for Video PresentationsFULL page Ad in conference programCompany Banner displayed at all the Sessions including Gala DinnerLogo on the conference website and main stageFlyer/promo gifts into congress bagsBranding at post-event communication activitiesAccess to all SessionsBusiness Lunches & Gala DinnerExclusive One-on-One Meetings Up to 5 delegates FREE-Admission (25% discount for extra ticket)VIP Airport Pick-up Service2 nights accommodation for 5 delegates registered
Speaking slot [up to 40min]6m2 exhibition space with LCD Monitor for Video Presentations½ page Ad in conference programCompany Banner displayed at the reception desk & Coffee breaksLogo on the conference website and main stageFlyer/promo gifts into congress bagsBranding at post-event communication activitiesAccess to all SessionsBusiness Lunches & Gala DinnerExclusive One-on-One Meetings Up to 4 delegates FREE-Admission (25% discount for extra ticket)VIP Airport Pick-up Service2 nights accommodation for 4 delegates registered
GOLD SPONSORSHIP 15,995€(VAT INC.) 12,995€(VAT INC.)
SPEAKER SPONSORSHIP
Speaking slot [up to 40min]6m2 exhibition space¼ page Ad in conference programCompany Banner displayed at the reception deskLogo on the conference website and main stageFlyer/promo gifts into congress bagsBranding at post-event communication activitiesAccess to all SessionsBusiness Lunches & Gala DinnerExclusive One-on-One Meetings Up to 3 delegates FREE-Admission (25% discount for extra ticket)VIP Airport Pick-up Service2 nights accommodation for 3 delegates registered
Speaking slot [up to 40min]3m2 exhibition spaceLogo on the conference website and main stageFlyer/promo gifts into congress bagsBranding at post-event communication activitiesAccess to all SessionsBusiness Lunches & Gala DinnerExclusive One-on-One Meetings Up to 2 delegates FREE-Admission (25% discount for extra ticket)
BRONZE SPONSORSHIP 8,995€(VAT INC.) 5,995€(VAT INC.)
EXHIBITION PACKAGE
Speaking slot [up to 40min]Logo on the conference website and main stageFlyer/promo gifts into congress bagsBranding at post-event communication activitiesAccess to all SessionsBusiness Lunches & Gala DinnerExclusive One-on-One Meetings Up to 1 delegates FREE-Admission (25% discount for extra ticket)
3m2 exhibition spaceLogo on the conference website and main stageFlyer/promo gifts into congress bagsBranding at post-event communication activitiesAccess to all SessionsBusiness Lunches & Gala DinnerExclusive One-on-One Meetings Up to 1 delegates FREE-Admission (25% discount for extra ticket)
KEYNOTE SPEECH PACKAGE 3,550€(VAT INC.) 3,550€(VAT INC.)
Click bellow to register as a sponsor
S P O N S O R S H I P P A C K A G E S
-dd mm yyyy
-
Yes No
ww
w.b
ioba
nkin
g.co
m
